Table 1 The MR analysis, heterogeneity and pleiotropy of COVID-19 infection on mRNFL, mGCIPL thickness
From: SARS-CoV-2 neurovascular invasion supported by Mendelian randomization
Method | Outcome | Exposure: COVID-19 infection | ||||||
|---|---|---|---|---|---|---|---|---|
N | Effect (SE) | P | OR | 95% CI | P-heterogeneity | P-pleiotropy | ||
IVW | mRNFL | 22 | 0.19 | 3.6 × 10–3 | 1.74 | 1.20–2.52 | 0.61 | |
Maximum likelihood | 22 | 0.19 | 2.82 × 10–3 | 1.77 | 1.22–2.58 | 0.61 | ||
MR Egger | 22 | 0.32 | 0.06 | 1.89 | 1.01–3.55 | 0.55 | ||
IVW (fixed effects) | 22 | 0.19 | 3.58 × 10–3 | 1.74 | 1.20–2.52 | – | ||
MR PRESSO | 22 | 0.18 | 0.26 | 1.19 | 1.17–2.34 | – | 0.74 | |
IVW | mGCIPL | 22 | 0.25 | 3.60 × 10–4 | 2.43 | 1.49–3.96 | 0.69 | |
Maximum likelihood | 22 | 0.25 | 2.50 × 10–3 | 2.50 | 1.53–4.08 | 0.70 | ||
MR Egger | 22 | 0.42 | 4.62 × 10–3 | 3.83 | 1.68–8.75 | 0.74 | ||
IVW (fixed effects) | 22 | 0.25 | 3.60 × 10–4 | 2.43 | 1.49–3.96 | – | ||
MR PRESSO | 22 | 0.25 | 0.60 | 1.29 | 1.27–3.43 | – | 0.19 | |